Sodium Bicarbonate Injection Shortage

Last Updated: September 16, 2025
Status: Current

Unavailable, Current:

• Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (Hospira, Inc., a Pfizer Company)
• Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (Hospira, Inc., a Pfizer Company)
• Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (Hospira, Inc., a Pfizer Company)
• Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (Hospira, Inc., a Pfizer Company)
• Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (Hospira, Inc., a Pfizer Company)
• Sodium Bicarbonate, Injection, 84 mg/1 mL (Fresenius Kabi USA, LLC)

Limited Availability, Current:

• Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (Hospira, Inc., a Pfizer Company)
• Sodium Bicarbonate, Injection, 42 mg/1 mL (Exela Pharma Sciences, LLC)
• Sodium Bicarbonate, Injection, 84 mg/1 mL (Exela Pharma Sciences, LLC)

Available, Current:

• Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (Hospira, Inc., a Pfizer Company)
• Sodium Bicarbonate, Injection, 42 mg/1 mL (Fresenius Kabi USA, LLC)
• Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (Hospira, Inc., a Pfizer Company)
• Sodium Bicarbonate, Injection, 84 mg/1 mL (Amphastar Pharmaceuticals, Inc.)
• Sodium Bicarbonate, Injection, 84 mg/1 mL (Exela Pharma Sciences, LLC)
• Sodium Bicarbonate, Injection, 84 mg/1 mL (Long Grove Pharmaceuticals LLC)

Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (Hospira, Inc., a Pfizer Company)

NDC Code: 0409-4900-14
Availability: Unavailable
Status: Current
Date of update: August 15, 2025
Update type: Revised
Reason for shortage: Other
Related Information: Next Delivery: January 2026; Estimated Recovery: March 2026
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Change date: January 3, 2025
Initial posting date: March 1, 2017
Contact info: 844-646-4398

Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (Hospira, Inc., a Pfizer Company)

NDC Code: 0409-4916-14
Availability: Unavailable
Status: Current
Date of update: August 15, 2025
Update type: Revised
Reason for shortage: Other
Related Information: Shortage per Manufacturer: Manufacturing Delay
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Change date: January 3, 2025
Initial posting date: March 1, 2017
Contact info: 844-646-4398

Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (Hospira, Inc., a Pfizer Company)

NDC Code: 0409-5534-14
Availability: Unavailable
Status: Current
Date of update: August 15, 2025
Update type: Revised
Reason for shortage: Other
Related Information: Next Delivery and Estimated Recovery: December 2025
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Change date: January 3, 2025
Initial posting date: March 1, 2017
Contact info: 844-646-4398

Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (Hospira, Inc., a Pfizer Company)

NDC Code: 0409-6625-35
Availability: Unavailable
Status: Current
Date of update: August 15, 2025
Update type: Revised
Reason for shortage: Other
Related Information: Next Delivery and Estimated Recovery: March 2026
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Change date: January 3, 2025
Initial posting date: March 1, 2017
Contact info: 844-646-4398

Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (Hospira, Inc., a Pfizer Company)

NDC Code: 0409-6637-14
Availability: Unavailable
Status: Current
Date of update: August 15, 2025
Update type: Revised
Reason for shortage: Other
Related Information: Shortage per Manufacturer: Manufacturing Delay
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Change date: January 3, 2025
Initial posting date: March 1, 2017
Contact info: 844-646-4398

Sodium Bicarbonate, Injection, 84 mg/1 mL (Fresenius Kabi USA, LLC)

NDC Code: 63323-089-50
Availability: Unavailable
Status: Current
Date of update: September 2, 2025
Update type: Reverified
Reason for shortage: Other
Related Information: Backordered. Next release October 2025. Check wholesalers for inventory.
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Initial posting date: July 24, 2017
Contact info: 888-386-1300

Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (Hospira, Inc., a Pfizer Company)

NDC Code: 0409-5555-02
Availability: Limited Availability
Status: Current
Date of update: August 15, 2025
Update type: Revised
Reason for shortage: Other
Related Information: Limited Supply Available. Next Delivery and Estimated Recovery: September 2025
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Change date: January 3, 2025
Initial posting date: March 1, 2017
Contact info: 844-646-4398

Sodium Bicarbonate, Injection, 42 mg/1 mL (Exela Pharma Sciences, LLC)

NDC Code: 51754-5012-4
Availability: Limited Availability
Status: Current
Date of update: September 15, 2025
Update type: Revised
Reason for shortage: Demand increase for the drug
Related Information: Next batch release expected in 2 weeks.
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Initial posting date: July 24, 2017
Contact info: 828-758-5474 ext. 154

Sodium Bicarbonate, Injection, 84 mg/1 mL (Exela Pharma Sciences, LLC)

NDC Code: 51754-5011-4
Availability: Limited Availability
Status: Current
Date of update: September 15, 2025
Update type: Revised
Reason for shortage: Demand increase for the drug
Related Information: Next batch release expected in 2 weeks.
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Initial posting date: July 24, 2017
Contact info: 828-758-5474 ext. 154

Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (Hospira, Inc., a Pfizer Company)

NDC Code: 0409-5555-01
Availability: Available
Status: Current
Date of update: August 15, 2025
Update type: Reverified
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Change date: January 3, 2025
Initial posting date: March 1, 2017
Contact info: 844-646-4398

Sodium Bicarbonate, Injection, 42 mg/1 mL (Fresenius Kabi USA, LLC)

NDC Code: 63323-083-05
Availability: Available
Status: Current
Date of update: September 2, 2025
Update type: Reverified
Related Information: Check wholesalers for inventory
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Initial posting date: July 24, 2017
Contact info: 888-386-1300

Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (Hospira, Inc., a Pfizer Company)

NDC Code: 0409-6625-14
Availability: Available
Status: Current
Date of update: August 15, 2025
Update type: Reverified
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Initial posting date: March 1, 2017
Contact info: 844-646-4398

Sodium Bicarbonate, Injection, 84 mg/1 mL (Amphastar Pharmaceuticals, Inc.)

NDC Code: 76329-3352-1
Availability: Available
Status: Current
Date of update: September 16, 2025
Update type: Reverified
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Initial posting date: March 1, 2017
Contact info: 800-423-4136

Sodium Bicarbonate, Injection, 84 mg/1 mL (Exela Pharma Sciences, LLC)

NDC Code: 51754-5001-5
Availability: Available
Status: Current
Date of update: September 15, 2025
Update type: Revised
Related Information: Clearing all backorders today.
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Initial posting date: July 24, 2017
Contact info: 828-758-5474 ext. 154

Sodium Bicarbonate, Injection, 84 mg/1 mL (Long Grove Pharmaceuticals LLC)

NDC Code: 81298-7620-3
Availability: Available
Status: Current
Date of update: June 27, 2025
Update type: Reverified
Therapeutic category: Endocrinology/Metabolism; Gastroenterology; Pediatric
Initial posting date: March 1, 2017
Contact info: 833-268-5559

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer